Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corvus Pharma Com 863 Mitten Road Suite102 BURLINGAME CA 94010 USA

www.corvuspharma.com Employees: 28 P: 650-900-4520

Description:

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.

Key Statistics

Overview:

Market Capitalization, $K 371,553
Enterprise Value, $K 358,933
Shares Outstanding, K 62,551
Annual Sales, $ 0 K
Annual Net Income, $ -27,030 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,260 K
EBIT, $ -23,400 K
EBITDA, $ -24,140 K
60-Month Beta 1.14
% of Insider Shareholders 31.30%
% of Institutional Shareholders 46.64%
Float, K 42,973
% Float 68.70%
Short Volume Ratio 0.20

Growth:

1-Year Return 307.48%
3-Year Return 20.00%
5-Year Return 63.19%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 68.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.07 on 08/06/24
Next Earnings Date 11/05/24
Earnings Per Share ttm -0.45
EPS Growth vs. Prev Qtr 41.67%
EPS Growth vs. Prev Year 50.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CRVS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -53.99%
Return-on-Assets % -44.75%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 6.89
Book Value/Share 0.82
Interest Coverage -2.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar